翰思艾泰-B(03378)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

03378 翰思艾泰-B

交易中 09-29 15:23:06

27.580

+0.380

+1.40%

最高27.580	最低27.020	成交量900.00
今开27.920	昨收27.200	日振幅2.06%
总市值36.96亿	流通市值36.96亿	总股本1.34亿
成交额2.47万	换手率0.00%	流通股本1.34亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"03378","market":"HK","secType":"STK","nameCN":"翰思艾泰-B","latestPrice":27.58,"timestamp":1790663484481,"preClose":27.2,"halted":0,"volume":900,"delay":0,"changeRate":0.013970588235294082,"floatShares":134000000,"shares":134000000,"eps":-1.11,"marketStatus":"交易中","change":0.38,"latestTime":"09-29 15:23:06","open":27.92,"high":27.58,"low":27.02,"amount":24744,"amplitude":0.020588,"askPrice":27.6,"askSize":100,"bidPrice":27.08,"bidSize":400,"shortable":0,"etf":0,"ttmEps":-1.129,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1790669400000},"marketStatusCode":2,"adr":0,"listingDate":1766419200000,"exchange":"SEHK","adjPreClose":27.2,"openAndCloseTimeList":[[1790645400000,1790654400000],[1790658000000,1790668800000]],"volumeRatio":0.102455,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/03378","defaultTab":"news","newsList":[{"id":"2669157053","title":"翰思艾泰-B(03378)与晶泰科技签署战略合作框架协议及XtalPi Science技术平台使用授权协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2669157053","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669157053?lang=zh_cn&edition=full","pubTime":"2026-09-21 18:47","pubTimestamp":1789987673,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰思艾泰-B 发布公告，本公司与深圳晶泰科技有限公司于近期正式签署了战略合作框架协议及XtalPi Science技术平台使用授权协议，探索AI for Science在抗体设计、创新分子设计及药物研发流程优化等领域的应用。根据该等协议，本公司拟按照实际研发需要，采购并使用由晶泰科技提供的XtalPi Science平台相关服务及使用额度，晶泰科技将向本公司提供相应的平台能力及必要技术支持。双方亦可根据业务需要，进一步商讨扩大XtalPiScience服务的使用规模及应用范围。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1498862.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1617","02228","BK1535","BK1173","BK1141","BK1161","03378"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100101282","title":"翰思艾泰-B（03378）与晶泰科技签署战略合作协议　探索AI赋能新药研发","url":"https://stock-news.laohu8.com/highlight/detail?id=1100101282","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100101282?lang=zh_cn&edition=full","pubTime":"2026-09-21 18:41","pubTimestamp":1789987273,"startTime":"0","endTime":"0","summary":"2026年9月21日，翰思艾泰生物医药科技（武汉）股份有限公司发布自愿公告称，已与深圳晶泰科技有限公司正式签署战略合作框架协议及XtalPi Science技术平台使用授权协议，探索AI for Science在抗体设计、创新分子设计及药物研发流程优化等领域的应用。根据协议，翰思艾泰将按实际研发需要采购并使用晶泰科技提供的XtalPi Science平台相关服务及使用额度，晶泰科技则向翰思艾泰提供平台能力及必要技术支持。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03378"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165122051","title":"翰思艾泰-B（武汉）达成协议，探索AI驱动药物研发与分子设计","url":"https://stock-news.laohu8.com/highlight/detail?id=1165122051","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165122051?lang=zh_cn&edition=full","pubTime":"2026-09-21 18:39","pubTimestamp":1789987150,"startTime":"0","endTime":"0","summary":"翰思艾泰-B（武汉）近日签署了一项合作协议，旨在将人工智能（AI）前沿技术应用于药物研发和分子设计领域。此举标志着该公司在“AI for Science”方向上迈出实质性步伐，为创新药开发注入智能化新动能。据悉，双方将围绕机器学习、深度学习等核心技术，共同探索加速候选药物发现、优化分子结构及提升研发效率的路径，以期在精准医疗和靶向治疗层面取得突破性进展。此次合作不仅凸显了AI在生命科学中的巨大潜力，也彰显了翰思艾泰秉持科技驱动创新的战略眼光。未来，公司有望借助智能化平台，显著缩短新药从实验室到临床的转化周期，进一步巩固其在生物医药领域的竞争优势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1535","BK1161","03378","BK1173"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197738282","title":"翰思艾泰-B 2026年中期财报营收0元，经调整净亏损3,324.10万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1197738282","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197738282?lang=zh_cn&edition=full","pubTime":"2026-09-21 16:57","pubTimestamp":1789981079,"startTime":"0","endTime":"0","summary":"翰思艾泰-B发布2026年中期财报，根据公告，报告期内并未产生主营业务营收，营收为0元。期内经调整净亏损为3,324.10万元，同比收窄约1.20%。其他收入及收益从530.00万元同比增长421.00%至2,761.40万元，主要由于出售联营公司产生的可变对价之公允价值收益增加。经营活动所用现金净额约为5,621.70万元，而上年同期为7,187.30万元，相较上期减少21.80%，管理层表示主要受管线研发投资节奏变化影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"翰思艾泰-B 2026年中期财报营收0元，经调整净亏损3,324.10万元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03378"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667684659","title":"翰思艾泰-B(03378)拟配售最多1340万份认股权证","url":"https://stock-news.laohu8.com/highlight/detail?id=2667684659","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667684659?lang=zh_cn&edition=full","pubTime":"2026-09-13 18:26","pubTimestamp":1789295210,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰思艾泰-B 发布公告，于2026年9月13日，公司拟配售最多1340万份认股权证，其附带权利可按初步认购价每股认购股份36港元认购最多1340万股认购股份。发行认股权证的所得款项净额预期将用作公司的一般营运资金，包括支付公司薪金、租金开支及其他办公费用。假设最高数目的认股权证所附认购权按初步认购价获悉数行使，预计将筹集额外所得款项总额最多约4.824亿港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495365.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1173","BK1535","03378","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117757222","title":"翰思艾泰-B（03378）拟特别授权配售最多1,340万份非上市认股权证 最高募资4.86亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1117757222","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117757222?lang=zh_cn&edition=full","pubTime":"2026-09-13 18:06","pubTimestamp":1789293969,"startTime":"0","endTime":"0","summary":"2026年9月13日，翰思艾泰生物医药科技（武汉）股份有限公司公告，与第一上海证券有限公司签订《认股权证配售协议》，计划按尽力基准向不少于7名独立第三方承配人配售最多13,400,000份非上市认股权证。初步认购价：每股36港元，可予调整。其中认股权证持有人将合计持有8.96%的股权。公司将尽快向联交所递交认购股份上市及买卖申请；认股权证本身不申请上市。临时股东大会将审议认股权证配售及特别授权等相关议案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03378"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189220324","title":"翰思艾泰-B发布8月月报表：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1189220324","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1189220324?lang=zh_cn&edition=full","pubTime":"2026-09-02 17:13","pubTimestamp":1788340417,"startTime":"0","endTime":"0","summary":"翰思艾泰生物医药科技（武汉）股份有限公司于2026年9月2日发布2026年8月股份变动月报表。报告期为2026年8月，期间公司注册股本及已发行股份未发生新增或减少变动。报告期初与期末的股份数量保持一致，普通股H股数量分别为134,060,730股，库藏股份为2,158,100股。截至月末，公司股本总数保持稳定。公司在公告中表示，所有关于证券发行及库藏股份处置事宜，均已按照相关法律和监管规定以及公司董事会的正式授权批准进行。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03378"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661293880","title":"翰思艾泰-B上半年研发开支2610.2万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2661293880","media":"经济参考网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661293880?lang=zh_cn&edition=full","pubTime":"2026-08-21 20:51","pubTimestamp":1787316673,"startTime":"0","endTime":"0","summary":"日前，翰思艾泰-B（03378.HK）公布截至2026年6月30日止六个月中期业绩。报告期内，公司实现其他收入及收益大幅增长，达到2761.4万元，同比增加421.02%；研发开支2610.2万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608213849575011.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608213849575011.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1535","BK1161","BK1173","03378"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660485304","title":"翰思艾泰-B(03378.HK)发布中期业绩 股东应占亏损3688.3万元 同比扩大1.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660485304","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660485304?lang=zh_cn&edition=full","pubTime":"2026-08-17 16:42","pubTimestamp":1786956175,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","BK1173","03378","BK1535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136334841","title":"翰思艾泰-B（03378）披露2026年中期业绩：净亏损3324万元，研发投入同比降16.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1136334841","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136334841?lang=zh_cn&edition=full","pubTime":"2026-08-17 16:36","pubTimestamp":1786955813,"startTime":"0","endTime":"0","summary":"2026年8月17日，翰思艾泰生物医药科技（武汉）股份有限公司发布截至2026年6月30日止六个月未审计中期业绩。报告期内，公司继续推进肿瘤免疫、抗体偶联药物和自身免疫治疗等多元管线开发，并取得多项临床进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03378"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189779641","title":"翰思艾泰-B（03378）拟于8月17日召开董事会审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1189779641","media":"公告速递","labels":["conferences","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1189779641?lang=zh_cn&edition=full","pubTime":"2026-08-05 16:53","pubTimestamp":1785919980,"startTime":"0","endTime":"0","summary":"翰思艾泰生物医药科技（武汉）股份有限公司（03378）8月5日发布公告称，公司董事会会议将于2026年8月17日（星期一）举行，拟审议并批准公司及其附属公司截至2026年6月30日止六个月的中期业绩及其发布事宜，并处理其他事项。\n公告显示，截至公告日，公司董事会成员包括：\n1. 执行董事：张发明博士、李其翔博士、肖婕妤女士、刘敏先生；\n2. 非执行董事：李健博士；\n3. 独立非执行董事：毕红钢博士、陈奇峰先生、王世雄先生、张瓊光博士。\n此次董事会会议结果及中期业绩公布时间表，须以公司后续公告为准。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03378"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127537332","title":"翰思艾泰-B 7月股份变动月报：回购46.25万股转为库存","url":"https://stock-news.laohu8.com/highlight/detail?id=1127537332","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127537332?lang=zh_cn&edition=full","pubTime":"2026-08-04 17:36","pubTimestamp":1785836183,"startTime":"0","endTime":"0","summary":"翰思艾泰生物医药科技（武汉）股份有限公司于2026年8月4日发布了截至2026年7月31日的证券变动月报表。报告显示，本月公司注册股份总数保持不变，仍为136,218,830股。根据公告，本月公司已发行股份由134,523,230股减少至134,060,730股，库存股份由1,695,600股增至2,158,100股，变动均来自于当月共回购的462,500股H股，回购价格区间为每股港币28.4286元至29.0891元。上述回购股份目前以库存方式持有，尚未完成注销。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03378"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655828591","title":"港股异动 | 翰思艾泰-B(03378.HK)涨超4% 近期拟与华科前沿交叉研究中心打造新一代AI驱动创新药研发范式","url":"https://stock-news.laohu8.com/highlight/detail?id=2655828591","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655828591?lang=zh_cn&edition=full","pubTime":"2026-07-30 14:00","pubTimestamp":1785391258,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["03378","BK1161","BK1173","BK1535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652400436","title":"翰思艾泰-B(03378.HK)7月17日斥资171.99万港元回购6.05万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652400436","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652400436?lang=zh_cn&edition=full","pubTime":"2026-07-17 19:38","pubTimestamp":1784288282,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1535","03378","BK1161","BK1173"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152145952","title":"翰思艾泰-B于7月17日回购6.05万股，涉资约171.99万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1152145952","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1152145952?lang=zh_cn&edition=full","pubTime":"2026-07-17 19:35","pubTimestamp":1784288152,"startTime":"0","endTime":"0","summary":"翰思艾泰生物医药科技（武汉）股份有限公司于2026年7月17日公告称，公司在香港联交所场内回购60,500股H股股份，约占回购前已发行股本的0.045%。本次回购价介乎每股27.42港元至29.50港元，合计耗资1,719,928港元。公司于2026年6月24日召开会议通过了本次回购授权，授权回购股份总数为13,469,683股。截至本次回购完成，公司已累计回购636,100股，占授权当日已发行股本总数的0.4722%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"翰思艾泰-B于7月17日回购6.05万股，涉资约171.99万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03378"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187738660","title":"翰思艾泰-B 7月16日回购15,600股股份，耗资约45.38万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1187738660","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187738660?lang=zh_cn&edition=full","pubTime":"2026-07-16 18:33","pubTimestamp":1784198002,"startTime":"0","endTime":"0","summary":"翰思艾泰生物医药科技（武汉）股份有限公司于2026年7月16日发布翌日披露报表，披露其于当日于香港联交所场内回购15,600股H股普通股。该数量约占回购前公司已发行股份总数134,136,830股的0.012%，回购价介乎每股28.94港元至29.68港元，合计耗资约45.38万港元。回购完成后，公司已发行股本变动为134,121,230股，库存股份增加至2,097,600股。根据公告，股东大会已于2026年6月24日通过股份购回授权，总额度为13,469,683股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"翰思艾泰-B 7月16日回购15,600股股份，耗资约45.38万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03378"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111871776","title":"翰思艾泰-B回购5.57万股股份，总额约161.26万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1111871776","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111871776?lang=zh_cn&edition=full","pubTime":"2026-07-15 19:35","pubTimestamp":1784115358,"startTime":"0","endTime":"0","summary":"翰思艾泰生物医药科技（武汉）股份有限公司于2026年7月15日公告，披露公司在香港联交所场内回购股份。此次回购涉及5.57万股，占回购前公司已发行股本约0.042%。回购价介乎每股28.66港元至29.90港元，总代价约为161.26万港元。回购完成后，公司已发行股本总数维持136,218,830股，库藏股增至2,082,000股。根据公告，公司回购授权于2026年6月24日获股东大会通过，可回购总数为13,469,683股。截至目前，公司已通过香港联交所及其他证券交易所累计回购560,000股，剩余授权额度为12,909,683股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"翰思艾泰-B回购5.57万股股份，总额约161.26万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03378"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651450359","title":"翰思艾泰-B(03378.HK)7月15日斥资161.26万港元回购5.57万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651450359","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651450359?lang=zh_cn&edition=full","pubTime":"2026-07-15 19:33","pubTimestamp":1784115186,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","BK1535","03378","BK1173"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184011115","title":"翰思艾泰-B 7月14日回购5.82万股，涉资约168.49万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1184011115","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184011115?lang=zh_cn&edition=full","pubTime":"2026-07-14 19:35","pubTimestamp":1784028947,"startTime":"0","endTime":"0","summary":"翰思艾泰生物医药科技（武汉）股份有限公司于2026年7月14日回购公司股份。据公告披露，本次回购数量为58,200股，占该事件前公司已发行股本约0.043%。回购价格区间介乎每股28.5港元至29.88港元，合计支付约168.49万港元。本次回购完成后，截至2026年7月14日收市，公司已发行股本数量由回购前的134,250,730股减少至134,192,530股，库藏股数量由1,968,100股增至2,026,300股，总发行股本仍为136,218,830股。公司同时确认已经遵守相关上市规则及适用法律规定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"翰思艾泰-B 7月14日回购5.82万股，涉资约168.49万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03378"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651170465","title":"翰思艾泰-B(03378.HK)7月14日斥资168.49万港元回购5.82万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651170465","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651170465?lang=zh_cn&edition=full","pubTime":"2026-07-14 19:26","pubTimestamp":1784028404,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["03378","BK1161","BK1535","BK1173"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hanxbio.com/","stockEarnings":[{"period":"1week","weight":-0.0823},{"period":"1month","weight":-0.1175},{"period":"3month","weight":-0.049},{"period":"6month","weight":-0.1526},{"period":"1year","weight":-0.15},{"period":"ytd","weight":0.7021}],"compareEarnings":[{"period":"1week","weight":-0.016},{"period":"1month","weight":-0.0368},{"period":"3month","weight":0.077},{"period":"6month","weight":-0.0258},{"period":"1year","weight":-0.0569},{"period":"ytd","weight":-0.0385}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"翰思艾泰生物医药科技（武汉）股份有限公司是一家主要从事肿瘤免疫疗法的研发的中国公司。该公司的产品管线有针对肿瘤学的临床阶段候选药物和临床前阶段候选药物，包括核心产品HX009及主要产品HX301及HX044，以及针对自身免疫和肿瘤市场的抗体偶联药物、双特异性抗体及单克隆抗体。HX009是一种自主研发的抗程序性细胞死亡蛋白1（PD-1）/信号调节蛋白α（SIRPα）双功能抗体融合蛋白。HX301是一种靶向集落刺激因子-1受体（CSF1R）、AMPK相关蛋白激酶5（ARK5）、FMS样酪氨酸激酶3（FLT-3）及细胞周期蛋白依赖性激酶4/6（CDK4/6）等关键通路的多靶点激酶抑制剂。HX044为一种新型双重功能抗细胞毒性T淋巴细胞相关蛋白4（CTLA-4）抗体SIRPα融合蛋白。","yearOnYearQuotes":[{"month":1,"riseRate":0.588235,"avgChangeRate":0.005427},{"month":2,"riseRate":0.411765,"avgChangeRate":0.008835},{"month":3,"riseRate":0.352941,"avgChangeRate":-0.021319},{"month":4,"riseRate":0.705882,"avgChangeRate":0.100651},{"month":5,"riseRate":0.352941,"avgChangeRate":0.046508},{"month":6,"riseRate":0.470588,"avgChangeRate":-0.00883},{"month":7,"riseRate":0.470588,"avgChangeRate":0.004276},{"month":8,"riseRate":0.470588,"avgChangeRate":-0.031033},{"month":9,"riseRate":0.588235,"avgChangeRate":-0.013577},{"month":10,"riseRate":0.75,"avgChangeRate":0.019136},{"month":11,"riseRate":0.625,"avgChangeRate":0.009468},{"month":12,"riseRate":0.625,"avgChangeRate":0.056179}],"exchange":"SEHK","name":"翰思艾泰-B","nameEN":"HANXBIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"翰思艾泰-B(03378)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供翰思艾泰-B(03378)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"翰思艾泰-B,03378,翰思艾泰-B股票,翰思艾泰-B股票老虎,翰思艾泰-B股票老虎国际,翰思艾泰-B行情,翰思艾泰-B股票行情,翰思艾泰-B股价,翰思艾泰-B股市,翰思艾泰-B股票价格,翰思艾泰-B股票交易,翰思艾泰-B股票购买,翰思艾泰-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"翰思艾泰-B(03378)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供翰思艾泰-B(03378)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}